Limits...
Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial.

Arjyal A, Basnyat B, Koirala S, Karkey A, Dongol S, Agrawaal KK, Shakya N, Shrestha K, Sharma M, Lama S, Shrestha K, Khatri NS, Shrestha U, Campbell JI, Baker S, Farrar J, Wolbers M, Dolecek C - Lancet Infect Dis (2011)

Bottom Line: Late relapses were noted in three of 175 patients in the culture-confirmed chloramphenicol group and two of 177 in the gatifloxacin group.There were no culture-positive relapses after day 62. 99 patients (24%) experienced 168 adverse events in the chloramphenicol group and 59 (14%) experienced 73 events in the gatifloxacin group.Wellcome Trust.

View Article: PubMed Central - PubMed

Affiliation: Oxford University Clinical Research Unit-Patan Academy of Health Sciences, Kathmandu, Nepal.

Show MeSH

Related in: MedlinePlus

Trial profile*Two culture-positive patients in both the chloramphenicol and glatifloxacin groups were lost to follow-up before day 8.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3108101&req=5

fig1: Trial profile*Two culture-positive patients in both the chloramphenicol and glatifloxacin groups were lost to follow-up before day 8.

Mentions: Of 1151 patients assessed, 853 were assigned treatment; 844 were analysed, 418 assigned chloramphenicol and 426 gatifloxacin (figure 1). The baseline characteristics of the patients were similar in the two treatment groups (table 1). The proportion of patients with treatment failure was similar in the two treatment groups in patients with culture-positive disease (table 2). Of the five patients with persistent fever on day 10 in the gatifloxacin group (table 2), two became afebrile on day 11 and did not require rescue treatment. The other three patients were effectively treated with intravenous ceftriaxone 50 mg/kg per day in a single dose for 7 days. The five patients in the chloramphenicol group who needed rescue treatment were successfully treated with ofloxacin 20 mg/kg per day in two divided doses per day for 7 days. In all cases, rescue treatment was initiated on either day 10 or day 11.


Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial.

Arjyal A, Basnyat B, Koirala S, Karkey A, Dongol S, Agrawaal KK, Shakya N, Shrestha K, Sharma M, Lama S, Shrestha K, Khatri NS, Shrestha U, Campbell JI, Baker S, Farrar J, Wolbers M, Dolecek C - Lancet Infect Dis (2011)

Trial profile*Two culture-positive patients in both the chloramphenicol and glatifloxacin groups were lost to follow-up before day 8.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3108101&req=5

fig1: Trial profile*Two culture-positive patients in both the chloramphenicol and glatifloxacin groups were lost to follow-up before day 8.
Mentions: Of 1151 patients assessed, 853 were assigned treatment; 844 were analysed, 418 assigned chloramphenicol and 426 gatifloxacin (figure 1). The baseline characteristics of the patients were similar in the two treatment groups (table 1). The proportion of patients with treatment failure was similar in the two treatment groups in patients with culture-positive disease (table 2). Of the five patients with persistent fever on day 10 in the gatifloxacin group (table 2), two became afebrile on day 11 and did not require rescue treatment. The other three patients were effectively treated with intravenous ceftriaxone 50 mg/kg per day in a single dose for 7 days. The five patients in the chloramphenicol group who needed rescue treatment were successfully treated with ofloxacin 20 mg/kg per day in two divided doses per day for 7 days. In all cases, rescue treatment was initiated on either day 10 or day 11.

Bottom Line: Late relapses were noted in three of 175 patients in the culture-confirmed chloramphenicol group and two of 177 in the gatifloxacin group.There were no culture-positive relapses after day 62. 99 patients (24%) experienced 168 adverse events in the chloramphenicol group and 59 (14%) experienced 73 events in the gatifloxacin group.Wellcome Trust.

View Article: PubMed Central - PubMed

Affiliation: Oxford University Clinical Research Unit-Patan Academy of Health Sciences, Kathmandu, Nepal.

Show MeSH
Related in: MedlinePlus